Jacob Van Naarden, Loxo COO (Loxo)

#ASH20 Loxo and Eli Lil­ly show off PhI/II da­ta for their BTK in­hibitor in two blood can­cers

ASH is back and Loxo is primed and ready to present new da­ta that they think will be quite ex­cit­ing.

The Lil­ly-owned com­pa­ny is an­nounc­ing re­sults from a Phase I/II tri­al on its LOXO-305 pro­gram, and Sat­ur­day af­ter­noon they de­tailed da­ta in pa­tients with man­tle cell lym­phoma (MCL) and oth­er non-Hodgkin lym­phomas. And Mon­day morn­ing, Loxo added to their da­ta port­fo­lio with re­sults from the pro­gram in chron­ic lym­pho­cyt­ic leukemia (CLL) and small lym­pho­cyt­ic lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.